Comparative Pharmacology
Head-to-head clinical analysis: PHRENILIN versus SODIUM PENTOBARBITAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHRENILIN versus SODIUM PENTOBARBITAL.
PHRENILIN vs SODIUM PENTOBARBITAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PHRENILIN is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate that enhances GABA-A receptor activity, producing sedation. Acetaminophen inhibits cyclooxygenase (COX) in the CNS, reducing prostaglandin synthesis. Caffeine is a nonselective adenosine receptor antagonist, promoting vasoconstriction and enhancing analgesic effects.
Barbiturate that enhances GABA-A receptor activity, prolonging chloride channel opening and increasing inhibitory neurotransmission. At high doses, it acts as a GABA mimetic and depresses neuronal excitability.
For tension headache: 1-2 capsules (each containing butalbital 50 mg, acetaminophen 300 mg, and caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.
IV: 100-150 mg administered over 1-2 minutes for induction of anesthesia; for seizure control, 100 mg IV every 5-10 minutes up to 500 mg. For maintenance of anesthesia, 50 mg IV as needed every 15-30 minutes. IM: 150-200 mg for preoperative sedation.
None Documented
None Documented
Butalbital: terminal half-life ~35 hours (range 20-50 h); acetaminophen: ~2-3 hours (prolonged in hepatic impairment); caffeine: ~3-6 hours.
15-50 hours (dose-dependent; prolonged in hepatic impairment).
PHRENILIN (butalbital/acetaminophen/caffeine): Renal excretion of metabolites; butalbital ~60-70% unchanged in urine, acetaminophen ~2-4% unchanged with majority as glucuronide and sulfate conjugates, caffeine metabolites primarily renal.
Renal (25-50% unchanged); hepatic metabolism to inactive metabolites; fecal <5%.
Category C
Category D/X
Barbiturate/Analgesic Combination
Barbiturate